제넥신

095700KOSDAQ자연과학 및 공학 연구개발업

52.8 / 100

Reference Date: 2026-06-10

Financial Score25.5 / 40

News Sentiment15.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Plunged 42.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genexine focuses on developing innovative therapies for cancer and immune-related diseases using its proprietary bioPROTAC technology, which leverages biologics like nanobodies to overcome limitations of traditional small-molecule-based PROTAC approaches. The company aims to effectively degrade target proteins by utilizing advanced targeted protein degradation techniques, enabling precise and efficient disease treatment.

Number of Employees

68people

Average Salary

82.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

0.56Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-10.71Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

3.10Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.9% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 3Neutral 2Negative 3Average Sentiment Score 61.2

Positive
제넥신 "빈혈치료제 '에페사' 허가 재신청 추진"
제넥신의 빈혈치료제 '에페사' 재허가 신청으로 인해 기업의 신약 개발 성공 가능성이 높아져 긍정적인 시장 반응 예상.
Negative
제넥신 ' 에페사' 품목허가 반려…"품질 문제 보완할 것"
제넥신의 주요 신약 '에페사' 품목허가가 품질 문제로 반려되어 개발에 차질이 예상된다.
Negative
제넥신, 빈혈치료제 'GX-E4' 국내 허가 반려…"수개월 내 재신청"
제넥신의 주요 신약 GX-E4의 국내 허가 반려로 인해 회사의 상용화 계획에 차질이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,010Won52-week high 7,10052-week low 3,010

1-month return0.0Point

1m -42.12% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항 (에페사프리필드시린지주(GX-E4) 한국 품목허가 신청결과)2026-06-04
Neutral분기보고서 (2026.03)2026-05-14